Why the study?
Does combined treatment with HBB and guanidine prevent paralysis and death in newborn mice infected with Echo virus 9 or Coxsackie A 9?
Does combined treatment with HBB and guanidine prevent paralysis and death in newborn mice infected with Echo virus 9 or Coxsackie A 9?
Combined treatment with HBB and guanidine protects newborn mice from paralysis and death caused by Echo virus 9 or Coxsackie A 9 infection.
Answers are grounded in this paper and cite their sources.
Supports preclinical testing of HBB-guanidine combinations; leaves open translation to human enteroviral disease.
Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity.
No takes yet. Share an insight, caveat, or question.
Hans J. Eggers (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: